ImmunoGen, Inc.

Good morning and welcome to ImmunoGen 3rd Quarter 2020 Financial and Operating Results Conference Call. Today's conference is being recorded. Now I'd like to turn the call over to Courtney Okonek, Senior Director of Corporate Communications and Investor Relations. Please go ahead.

Good morning and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent progress and third quarter 2020 financial results. This press release and a web stream of this call can be found under the Investor and Media section of Immunogen.com. With me today are Mark Ennedy, our President and CEO, Susan Altshuler, our Chief Financial Officer, and Anna Birkenblit, our Chief Medical Officer. Stacey Cohen, our Chief Business Officer, will also join us for Q&A. During today's call, we will review key accomplishments for the business over the last three months, our financial results, and upcoming milestones. During the discussion, we will use forward-looking statements, and our actual results may differ materially from such statements. Descriptions of the risks and uncertainties associated with an investment in Immunogen are included in our SEC filings. And with that, I'll turn the call over to Mark.

Thanks, Courtney. Good morning, everyone, and thank you for joining us today. We've generated significant momentum in the business over the last several months, achieving a number of important milestones across the company while managing the challenges of operating in the COVID environment. Starting with our lead program, we were pleased to announce our strategic collaboration with Huadong Medicine to develop and commercialize Mervituximab in Greater China. This is the second largest pharmaceutical market in the world, and Huadong's extensive research, development, and regulatory capabilities along with its access to a large network of local hospitals, will allow us to realize Mervituximab's potential to improve outcomes and bring more good days to women living with ovarian cancer in the region. This partnership further strengthens our balance sheet with an upfront payment of $40 million, additional milestone payments of up to $265 million, and tiered royalties on commercial sales. We look forward to working with Huadong to bring Mervituximab to the market in greater China And I thank the teams at Lazard and Ropes and Gray for their support in bringing this deal to fruition. Beyond Greater China, we are working with a sense of urgency to execute on our pivotal trials and prepare for the first potential launch of Mervituximab in 2022 in the U.S. To this end, we continue to advance site activation and patient enrollment for both Soraya and Mirasol and are on track to report top-line data from Soraya in Q3 next year. In addition to a potential monotherapy label, we are committed to moving into earlier lines of therapy by combining with other agents. With the benefit of the encouraging data we shared at ASCO and ESMO earlier this year, we are working to define the best path to label expansion with our combination regimen and look forward to sharing our approach in a future call. Moving to our earlier stage programs, we were delighted to receive breakthrough therapy designation from FDA for IMGN 632 for the treatment of relapsed or refractory BPDCN, underscoring the need for safe and effective treatments for this rare and aggressive cancer. We are engaged with FDA to further define the development path for BPDCN while continuing to evaluate 632 and AML and other hematological malignancies. Finally, through effective execution and business development and deployment of our ATM facility, We have further strengthened our balance sheet and now expect our existing cash, together with future payments from our partners, to fund our operations into the second half of 2022. With that, I'll turn the call over to Anna to review our clinical programs in more detail. Anna?